Cubist Pharmaceuticals Announce New Zurich Office

Cubist Pharmaceuticals, who specialise in the development of antibiotics for infectious diseases, has announced the launch of their new international headquarters based in Zurich, Switzerland. The new office will expand Cubist’s presence outside of the US, allowing the company to reinforce their commitment to the major public health threat of antimicrobial resistance. Patrick Vink, who

Continue Reading

Reckitt to Spinoff their Pharmaceutical Business

Reckitt Benckiser have today announced that they are planning on separating their pharmaceutical business, as they continue to concentrate on consumer health and hygiene. The process to separate RB Pharmaceuticals to be a separate UK listing is expected to occur within the next 12 months. The decision was founded from Reckitt’s belief that the division

Continue Reading

Biogen Idec Posts Positive Q2 2014 Results

Biogen Idec yesterday announced positive second-quarter financial results for 2014. The results were boosted by sales of their oral multiple sclerosis drug, Tecfidera, which increased net profits by 46%, comfortably passing analyst forecasts. Earnings for Biogen reached $714.5 million, while revenues jumped 40% to reach $2.06 billion. The company’s biggest earners were their multiple sclerosis

Continue Reading

ProStrakan Acquires Archimedes for £230 Million

ProStrakan, which is owned by Japan’s Kyowa Hakko Kirin, has announced that they will be acquiring UK cancer pain specialist, Archimedes Pharma, for £230 million in cash. ProStrakan, which is based in Scotland, is purchasing Reading-based Archimedes from Denmark’s Novo Nordisk Foundation. Archimedes posted sales revenues of £41 million last year, an increase of 33%. 

Continue Reading

Medtronic Acquires Covidien in $42.9 Billion Deal

US medtech company, Medtronic have confirmed the purchase of Ireland’s Covidien for $42.9 billion in cash and stock. Medtronic is the second-largest maker of medical devices, and once the transaction has been completed, the company noted that will have “significantly advanced” their position as a global “premier medical technology and services company.” The combined group,

Continue Reading

Positive Clinical Trial Results for Bristol-Myers Squibb’s Immunotherapy Combo

Results of a clinical trial combining Bristol-Myers Squibb’s Yervoy and Nivolumab show an exceptional improvement in tumour regression and overall survival rate for patients with advanced melanoma. Mario Sznol of Yale University School of Medicine, reporting the results of the early-stage study, commented that “this is the first trial conducted with this combination in melanoma.” 

Continue Reading

Bristol-Myers Squibb Announce Oncology Research Collaborations with CytomX and Incyte

Bristol-Myers Squibb (B-MS) yesterday announced a worldwide research partnership and license agreement with CytomX. The collaboration plans to discover, develop and commercialise novel therapies against multiple immuno-oncology targets using CytomX’s proprietary Probody Platform. Probodies are monoclonal antibodies selectively activated within the cancer microenvironment, to focus the activity of therapeutic antibodies to tumours and helping spare

Continue Reading

Valeant Pharmaceuticals Plan Improved Allergan Bid

Valeant yesterday confirmed that they are planning on making an improved, bigger offer for Allergan after their initial unsolicited $46 billion takeover offer was rejected. US pharmaceutical company, Allergan, who are best-known for their Botox, rejected Valeant and investor Bill Ackman’s Pershing Square Capital Management’s offer earlier this week, commenting that the offer substantially undervalues

Continue Reading